Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Javelin Biotech Inc. has 3 pending office actions in Chemistry & Materials. The matters are assigned to 3 examiners across 3 art units. ABEL, LENORA A is the busiest identified examiner, with 1 pending action.
The one-to-one distribution indicates separate examination paths for the pending matters. Counsel should coordinate overall portfolio objectives while tailoring each response to its assigned examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABEL, LENORA A | 1 | 68.7% | +33.8% |
| ALABI, OYELEYE A | 1 | 83.9% | +23.8% |
| RYAN, DOUGLAS CHARLES | 1 | 38.2% | +48.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18340495 | NEURODEGENERATIVE TARGET DISCOVERY PLATFORM | ALABI, OYELEYE A | — |
| 17104708 | MICROFLUIDIC PLATFORM FOR TARGET AND BIOMARKER DISCOVERY FOR NON-ALCOHOLIC FATTY LIVER DISEASE | RYAN, DOUGLAS CHARLES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18503912 | Tapping Device for Microfluidic System | ABEL, LENORA A | — |
| 18340495 | NEURODEGENERATIVE TARGET DISCOVERY PLATFORM | ALABI, OYELEYE A | — |
| 17104708 | MICROFLUIDIC PLATFORM FOR TARGET AND BIOMARKER DISCOVERY FOR NON-ALCOHOLIC FATTY LIVER DISEASE | RYAN, DOUGLAS CHARLES | — |
| Art Unit | Apps |
|---|---|
| 1799 | 1 |
| 1797 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18503912 | Tapping Device for Microfluidic System | ABEL, LENORA A | 1799 | §102 | Final Rejection | — | Pending | Nov 07, 2023 |
| 18340495 | NEURODEGENERATIVE TARGET DISCOVERY PLATFORM | ALABI, OYELEYE A | 1797 | §102§103 | Non-Final OA | — | Pending | Jun 23, 2023 |
| 17104708 | MICROFLUIDIC PLATFORM FOR TARGET AND BIOMARKER DISCOVERY FOR NON-ALCOHOLIC FATTY LIVER DISEASE | RYAN, DOUGLAS CHARLES | 1635 | §103§112 | Final Rejection | — | Pending | Nov 25, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJavelin Biotech Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Lenora A Abel has the most, with 1 of Javelin Biotech Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
